

# INSPIRATION-S


#ACC21



AMERICAN  
COLLEGE of  
CARDIOLOGY

**Trial Description:** Patients admitted to the ICU with COVID-19 infection were randomized to atorvastatin 20 mg daily vs. placebo.

p = 0.35



■ Atorvastatin 20 mg (n = 303) ■ Placebo (n = 302)

## RESULTS

- All-cause death, venous or arterial thrombosis, or treatment with extracorporeal membrane oxygenation: 32.7% of the atorvastatin group vs. 36.3% of the placebo group (p = 0.35)

## CONCLUSIONS

- Among critically ill patients with COVID-19 infection, atorvastatin was not beneficial
- Atorvastatin was not associated with a reduction in composite adverse events compared with placebo

Presented by Dr. Behnood Bikdeli at ACC.21